Carter Gould
Stock Analyst at Barclays
(3.49)
# 938
Out of 4,761 analysts
197
Total ratings
49.15%
Success rate
4.61%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Overweight | $160 → $165 | $120.69 | +36.71% | 12 | Dec 23, 2024 | |
| GILD Gilead Sciences | Maintains: Equal-Weight | $84 → $95 | $109.95 | -13.60% | 14 | Nov 7, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,080 → $1,065 | $700.33 | +52.07% | 19 | Nov 1, 2024 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $18 → $20 | $21.98 | -9.01% | 6 | Nov 1, 2024 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,025 → $975 | $873.68 | +11.60% | 11 | Oct 31, 2024 | |
| BIIB Biogen | Maintains: Equal-Weight | $190 → $180 | $140.64 | +27.99% | 24 | Oct 31, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Underweight | $42 → $43 | $55.83 | -22.98% | 14 | Oct 7, 2024 | |
| MRK Merck & Co. | Maintains: Overweight | $142 → $140 | $89.50 | +56.42% | 10 | Oct 7, 2024 | |
| AMGN Amgen | Maintains: Equal-Weight | $300 → $315 | $303.01 | +3.96% | 16 | Oct 7, 2024 | |
| ABBV AbbVie | Maintains: Overweight | $200 → $212 | $202.08 | +4.91% | 14 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $100 | $79.49 | +25.80% | 1 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $3 | $1.37 | +118.98% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $32 | $26.30 | +21.67% | 14 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3 | $1.00 | +200.00% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $2.57 | +250.19% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $95 | $50.26 | +89.02% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $20 | $27.53 | -27.35% | 5 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $73 | $63.75 | +14.51% | 4 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $1.5 → $1 | $0.29 | +250.02% | 4 | Jan 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $1.87 | +541.71% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $1.5 | $1.40 | +7.14% | 6 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $2.25 | $0.53 | +324.53% | 4 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $392 → $380 | $213.06 | +78.35% | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 → $82 | $72.11 | +13.72% | 5 | Jan 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $183 → $188 | $484.24 | -61.18% | 1 | Jul 26, 2018 |
Neurocrine Biosciences
Dec 23, 2024
Maintains: Overweight
Price Target: $160 → $165
Current: $120.69
Upside: +36.71%
Gilead Sciences
Nov 7, 2024
Maintains: Equal-Weight
Price Target: $84 → $95
Current: $109.95
Upside: -13.60%
Regeneron Pharmaceuticals
Nov 1, 2024
Maintains: Overweight
Price Target: $1,080 → $1,065
Current: $700.33
Upside: +52.07%
Travere Therapeutics
Nov 1, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $21.98
Upside: -9.01%
Eli Lilly and Company
Oct 31, 2024
Maintains: Overweight
Price Target: $1,025 → $975
Current: $873.68
Upside: +11.60%
Biogen
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $190 → $180
Current: $140.64
Upside: +27.99%
Bristol-Myers Squibb Company
Oct 7, 2024
Maintains: Underweight
Price Target: $42 → $43
Current: $55.83
Upside: -22.98%
Merck & Co.
Oct 7, 2024
Maintains: Overweight
Price Target: $142 → $140
Current: $89.50
Upside: +56.42%
Amgen
Oct 7, 2024
Maintains: Equal-Weight
Price Target: $300 → $315
Current: $303.01
Upside: +3.96%
AbbVie
Oct 7, 2024
Maintains: Overweight
Price Target: $200 → $212
Current: $202.08
Upside: +4.91%
Aug 29, 2024
Initiates: Overweight
Price Target: $100
Current: $79.49
Upside: +25.80%
Aug 14, 2024
Maintains: Overweight
Price Target: $10 → $3
Current: $1.37
Upside: +118.98%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $30 → $32
Current: $26.30
Upside: +21.67%
Jun 13, 2024
Maintains: Overweight
Price Target: $7 → $3
Current: $1.00
Upside: +200.00%
Jun 11, 2024
Initiates: Overweight
Price Target: $9
Current: $2.57
Upside: +250.19%
May 23, 2024
Maintains: Overweight
Price Target: $100 → $95
Current: $50.26
Upside: +89.02%
Apr 16, 2024
Maintains: Overweight
Price Target: $25 → $20
Current: $27.53
Upside: -27.35%
Feb 29, 2024
Maintains: Overweight
Price Target: $62 → $73
Current: $63.75
Upside: +14.51%
Jan 17, 2024
Maintains: Underweight
Price Target: $1.5 → $1
Current: $0.29
Upside: +250.02%
May 5, 2023
Maintains: Overweight
Price Target: $14 → $12
Current: $1.87
Upside: +541.71%
Mar 21, 2023
Maintains: Equal-Weight
Price Target: $2 → $1.5
Current: $1.40
Upside: +7.14%
Aug 16, 2022
Maintains: Equal-Weight
Price Target: $2.5 → $2.25
Current: $0.53
Upside: +324.53%
Jan 20, 2022
Maintains: Equal-Weight
Price Target: $392 → $380
Current: $213.06
Upside: +78.35%
Jan 16, 2019
Downgrades: Neutral
Price Target: $75 → $82
Current: $72.11
Upside: +13.72%
Jul 26, 2018
Maintains: Neutral
Price Target: $183 → $188
Current: $484.24
Upside: -61.18%